PD-L1 is widely expressed on the surface of tumor cells, and its high expression in the tumor microenvironment is generally regarded as a biomarker for anti-PD-1/PD-L1 immunotherapy in various tumors, especially in NSCLC [22,54,55]. The gene discussed is CD274; the disease is neoplasm.